ECSP13012593A - Derivados de 1,4-oxazepano - Google Patents

Derivados de 1,4-oxazepano

Info

Publication number
ECSP13012593A
ECSP13012593A ECSP13012593A ECSP13012593A EC SP13012593 A ECSP13012593 A EC SP13012593A EC SP13012593 A ECSP13012593 A EC SP13012593A EC SP13012593 A ECSP13012593 A EC SP13012593A
Authority
EC
Ecuador
Prior art keywords
ring
oxazepano
derivatives
optionally substituted
membered aromatic
Prior art date
Application number
Other languages
English (en)
Inventor
Nobuki Sakauchi
Ikuo Fujimori
Tetsuya Tsukamoto
Tomoya Yukawa
Yuji Ishichi
Masami Yamada
Taku Kamei
Yoshihisa Nakada
Yusuke Ohba
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44906302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012593(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of ECSP13012593A publication Critical patent/ECSP13012593A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporciona un compuesto que tiene una actividad inhibidora de la recaptación de monoamina, que está representado por la fórmula (I) en donde el anillo A es un anillo aromático de 6 miembros opcionalmente sustituido, el anillo B es los sustituyentes en el anillo A se unen opcionalmente para formar, junto con el anillo A, un anillo fusionado aromático de 9 ó 10 miembros opcionalmente sustituido y los demás símbolos son como se definen en la memoria descriptiva o una de sus sales.
ECSP13012593 2010-10-07 2013-04-29 Derivados de 1,4-oxazepano ECSP13012593A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010227864 2010-10-07
JP2011175336 2011-08-10

Publications (1)

Publication Number Publication Date
ECSP13012593A true ECSP13012593A (es) 2013-07-31

Family

ID=44906302

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012593 ECSP13012593A (es) 2010-10-07 2013-04-29 Derivados de 1,4-oxazepano

Country Status (26)

Country Link
US (2) US8722662B2 (es)
EP (1) EP2625170A1 (es)
JP (1) JP5873487B2 (es)
KR (1) KR20130116073A (es)
CN (1) CN103261176B (es)
AR (1) AR083313A1 (es)
AU (1) AU2011313150A1 (es)
BR (1) BR112013008420A2 (es)
CA (1) CA2813911A1 (es)
CL (1) CL2013000927A1 (es)
CO (1) CO6700872A2 (es)
CR (1) CR20130158A (es)
DO (1) DOP2013000074A (es)
EA (1) EA201390491A1 (es)
EC (1) ECSP13012593A (es)
GE (1) GEP20156295B (es)
IL (1) IL225189A0 (es)
MX (1) MX2013003749A (es)
NZ (1) NZ608499A (es)
PE (1) PE20140239A1 (es)
PH (1) PH12013500657A1 (es)
SG (1) SG188346A1 (es)
TW (1) TW201242956A (es)
UY (1) UY33650A (es)
WO (1) WO2012046882A1 (es)
ZA (1) ZA201302112B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104136431B (zh) * 2011-12-21 2017-03-15 小野药品工业株式会社 作为凝血因子XIa抑制剂的吡啶酮和嘧啶酮衍生物
US9475809B2 (en) * 2013-07-23 2016-10-25 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives and use thereof as factor xia/plasma
CN105693652B (zh) * 2014-11-27 2019-01-08 常州合全药业有限公司 一种4-叔丁基-5-乙基-6-氧亚基-1,4-噁吖庚环-4,5-二甲酸基酯的合成方法
EP3231803B1 (en) 2014-12-10 2020-07-01 ONO Pharmaceutical Co., Ltd. Dihydroindolizinone derivative
CA2984565A1 (en) 2015-05-08 2016-11-17 Vertellus Holdings Llc Processes for converting carboxamides to thiocarboxamides
WO2024251807A1 (en) * 2023-06-08 2024-12-12 Cybin Irl Limited Companion animal treatments
WO2025006617A2 (en) * 2023-06-27 2025-01-02 Armgo Pharma, Inc. Agents for treating disorders involving ryanodine receptors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3018222A (en) 1956-08-28 1962-01-23 Ravensberg G M B H Central stimulant and appetite depressant composition
US4010166A (en) * 1974-11-25 1977-03-01 Ciba-Geigy Corporation 1,4-Oxazepines
DE3242923A1 (de) * 1982-11-20 1984-05-24 Basf Ag, 6700 Ludwigshafen 7-phenyl-7-phenoxymethyl-hexahydro-1,4-oxazepine, ihre herstellung und verwendung
JPH11514333A (ja) 1995-03-14 1999-12-07 プレーシス ファーマスーティカルズ インコーポレイテッド アミロイドの凝集の調節剤
JP2992677B2 (ja) 1995-06-05 1999-12-20 武田薬品工業株式会社 骨形成促進医薬組成物
BR9707636A (pt) 1996-02-22 1999-07-27 Neurosearch As Composto composição farmacêutica uso de um composto e processos para preparar composto e para tratar um distúrbio ou doença de um organismo animal vivo
DE69733655T2 (de) 1996-08-27 2006-04-27 Praecis Pharmaceuticals, Inc., Cambridge beta-AMYLOID PEPTIDAGGREGATION REGULIERENDE PEPTIDE MIT D-AMINOSÄUREN
CA2406271A1 (en) 2000-04-18 2001-10-25 Cytovia, Inc. Substituted 1,4-thiazepine and analogs and their use as activators of caspases
TW200502221A (en) * 2002-10-03 2005-01-16 Astrazeneca Ab Novel lactams and uses thereof
GB0229743D0 (en) * 2002-12-20 2003-01-29 Arakis Ltd Novel benzoxazocines
GB0303852D0 (en) 2003-02-19 2003-03-26 Pfizer Ltd Triazole compounds useful in therapy
DK1945631T3 (da) 2005-10-28 2012-10-22 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer
EP1996202A1 (en) * 2006-03-10 2008-12-03 AstraZeneca AB Chemical compounds
EP2032558A1 (en) 2006-05-31 2009-03-11 F. Hoffmann-Roche AG Benzazepine derivatives as monoamine reuptake inhibitors
MX2009005449A (es) 2006-11-24 2009-06-02 Takeda Pharmaceutical Compuesto heteromonociclico y uso del mismo.
GB0721178D0 (en) 2007-10-29 2007-12-05 Glaxo Group Ltd Chemical compounds
WO2009119528A1 (ja) 2008-03-24 2009-10-01 武田薬品工業株式会社 複素環化合物
WO2010016554A1 (ja) 2008-08-07 2010-02-11 武田薬品工業株式会社 環状アミン化合物

Also Published As

Publication number Publication date
JP2013538786A (ja) 2013-10-17
AR083313A1 (es) 2013-02-13
TW201242956A (en) 2012-11-01
CN103261176B (zh) 2015-06-03
US20130267494A1 (en) 2013-10-10
WO2012046882A1 (en) 2012-04-12
NZ608499A (en) 2015-03-27
CA2813911A1 (en) 2012-04-12
JP5873487B2 (ja) 2016-03-01
KR20130116073A (ko) 2013-10-22
EA201390491A1 (ru) 2013-11-29
UY33650A (es) 2012-04-30
AU2011313150A1 (en) 2013-04-18
SG188346A1 (en) 2013-04-30
CL2013000927A1 (es) 2013-09-13
PE20140239A1 (es) 2014-03-07
CN103261176A (zh) 2013-08-21
DOP2013000074A (es) 2014-07-31
BR112013008420A2 (pt) 2016-06-28
US20120088748A1 (en) 2012-04-12
IL225189A0 (en) 2013-06-27
PH12013500657A1 (en) 2013-05-06
US8722662B2 (en) 2014-05-13
EP2625170A1 (en) 2013-08-14
CO6700872A2 (es) 2013-06-28
GEP20156295B (en) 2015-06-10
CR20130158A (es) 2013-05-03
ZA201302112B (en) 2013-12-23
MX2013003749A (es) 2013-05-09

Similar Documents

Publication Publication Date Title
CR20160296A (es) Benzamidas sustituidas y métodos para usarlas
CL2017001533A1 (es) Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas
ECSP13012593A (es) Derivados de 1,4-oxazepano
MX2020005498A (es) Inhibidores de cdk.
CR20140218A (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas iii
CR20140450A (es) Composicion para el control de plagas que incluye un derivado de iminopiridina novedoso
GT201400195A (es) Compuestos de heterociclilo como inhibidores de mek
CO2017000332A2 (es) Coŵpuestos heterocíclicos como receptores huérfanos relacionados con retinoide gamma-t (ror γt)
CR20140525A (es) Compuestos de N-alquiltriazol como antagonistas de LPAR
MX2016003199A (es) Compuestos de azapiridona y usos de los mismos.
CR20150250A (es) Nuevos derivados de piridina
CR20150061A (es) Compuesto de pirazolopirimidinas
DOP2014000033A (es) Aminoquinazolinas como inhibidores de quinasa
CR20140217A (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas ii
CY1118950T1 (el) Νεα παραγωγα πυραζολιου
UY35305A (es) Compuestos sustituidos como moduladores de la pro teína de activación de la 5-lipoxigenasa (flap)
CR20150440A (es) Nuevos derivados de piridina
BR112018002461A2 (pt) compostos para dispositivos opticamente ativos
CR20160459A (es) Nuevos derivados de piridina
MX2017007377A (es) Compuestos organicos.
CO6491037A2 (es) Derivados de pirazinooxazepina
BR112019014963A8 (pt) Compostos-bis para dispositivos opticamente ativos
CR20160448A (es) Nuevos derivados de piridina
CL2018001493A1 (es) Nuevos derivados de fenilo
ECSP13012535A (es) Compuesto heterocíclico y sus usos